Geoffrey Porges
Stock Analyst at SVB Leerink
(1.36)
# 3,303
Out of 4,711 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $26.36 | +112.44% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $15.52 | +28.87% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $15.50 | +545.16% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $701.85 | +21.11% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $46.96 | +2.21% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $263.38 | -17.99% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $175.58 | -23.11% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.57 | -4.93% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $92.57 | -18.98% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $47.71 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $9.59 | +4.28% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.40 | +7,400.00% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $397.27 | -55.95% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $15.21 | +452.27% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.60 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.34 | +887.99% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $13.51 | +351.52% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $146.47 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $26.36
Upside: +112.44%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $15.52
Upside: +28.87%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $15.50
Upside: +545.16%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $701.85
Upside: +21.11%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $46.96
Upside: +2.21%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $263.38
Upside: -17.99%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $175.58
Upside: -23.11%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.57
Upside: -4.93%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $92.57
Upside: -18.98%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $47.71
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $9.59
Upside: +4.28%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.40
Upside: +7,400.00%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $397.27
Upside: -55.95%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $15.21
Upside: +452.27%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $33.60
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.34
Upside: +887.99%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $13.51
Upside: +351.52%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $146.47
Upside: -